-
Catalent Biologics, IVERIC bio Ink Mfg. Pact
contractpharma
June 18, 2019
Paragon Gene Therapy, part of Catalent Biologics, will provide materials for preclinical and Phase 1/2 trials for IVERIC’s gene therapy product candidates.
-
Biogen Completes $800M Nightstar Acquisition
contractpharma
June 10, 2019
Gains two mid- to late-stage clinical assets and preclinical programs in ophthalmology.
-
Cleveland researchers test novel gene therapy for glioblastoma
worldpharmanews
June 10, 2019
Cleveland researchers test novel gene therapy for glioblastoma.
-
Aldevron to Build 14-Acre Gene Therapy Mfg. Campus
contractpharma
June 04, 2019
Annual capacity will exceed $1 billion of plasmid DNA, RNA, gene editing enzymes, and other biologics.
-
FDA approves first gene therapy for paediatric spinal muscular atrophy
europeanpharmaceuticalreview
May 30, 2019
The FDA has given approval to AveXis for the first treatment of paediatric spinal muscular atrophy (SMA).
-
FDA Approves First Gene Therapy Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy
drugs
May 29, 2019
FDA Approves First Gene Therapy Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy.
-
B dot Medical to develop ultra-compact proton cancer therapy
biospectrumasia
May 29, 2019
B dot Medical will continue to contribute in the fight against cancer through the development of proton cancer therapy and other pioneering cancer therapy systems.
-
Catalent Completes Paragon Acquisition
contractpharma
May 21, 2019
$1.2 billion deal for gene therapy leader is final.
-
SEP-363856 Receives FDA Breakthrough Therapy Designation
americanpharmaceuticalreview
May 16, 2019
Sunovion and PsychoGenics announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for SEP-363856 ...
-
Genetic therapy heals damage caused by heart attack
worldpharmanews
May 13, 2019
Researchers from King's College London have found that therapy that can induce heart cells to regenerate after a heart attack.